Based on the Chugai Pharmaceutical Co. Ltd. stock forecast from 0 analysts, the average analyst target price for Chugai Pharmaceutical Co. Ltd. is not available over the next 12 months. Chugai Pharmaceutical Co. Ltd.’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Chugai Pharmaceutical Co. Ltd. is Slightly Bullish , which is based on 9 positive signals and 6 negative signals. At the last closing, Chugai Pharmaceutical Co. Ltd.’s stock price was JPY 6,974.00. Chugai Pharmaceutical Co. Ltd.’s stock price has changed by +2.36% over the past week, +7.34% over the past month and +30.38% over the last year.
No recent analyst target price found for Chugai Pharmaceutical Co. Ltd.
No recent average analyst rating found for Chugai Pharmaceutical Co. Ltd.
Company Overview Chugai Pharmaceutical Co. Ltd.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd. Read Less
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Po...Read More
Frequently Asked Questions About Chugai Pharmaceutical Co. Ltd. (4519:TSE) Stock
Stock Target Advisor's fundamental analysis for Chugai Pharmaceutical Co. Ltd.'s stock is Slightly Bullish .
4519:TSE stock's dividend yield is 1.22%.
Our analysis grades 4519:TSE stock's dividend yield at F. This means that 4519:TSE stock's dividend yield is above 13% of the stocks in the Drug Manufacturers - General sector in the TSE exchange.
Based on this 4519:TSE may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on 4519:TSE's stock to indicate what its average analyst target is.
4519:TSE stock's Price/Earning ratio is 28.65.
Our analysis grades 4519:TSE stock's Price / Earning ratio at F. This means that 4519:TSE stock's Price/Earning ratio is above 50% of the stocks in the Drug Manufacturers - General sector in the TSE exchange.
Based on this 4519:TSE may be fairly valued for its sector
The last closing price of 4519:TSE's stock was JPY 6,974.00.
The most recent market capitalization for 4519:TSE is JPY 11,072.64B.
Unfortunately we do not have enough analyst data on 4519:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Chugai Pharmaceutical Co. Ltd.'s stock.
As per our most recent records Chugai Pharmaceutical Co. Ltd. has 7,604 Employees.
Chugai Pharmaceutical Co. Ltd.'s registered address is 2-1-1 Nihonbashi-Muromachi, Chuo, Japan, 103-8324.
You can get more information about it from Chugai Pharmaceutical Co. Ltd.'s website at https://www.chugai-pharm.co.jp.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Chugai Pharmaceutical Co. Ltd. (4519:TSE) Stock
Stock Target Advisor's fundamental analysis for Chugai Pharmaceutical Co. Ltd.'s stock is Slightly Bullish .
4519:TSE stock's dividend yield is 1.22%.
Our analysis grades 4519:TSE stock's dividend yield at F. This means that 4519:TSE stock's dividend yield is above 13% of the stocks in the Drug Manufacturers - General sector in the TSE exchange.
Based on this 4519:TSE may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on 4519:TSE's stock to indicate what its average analyst target is.
4519:TSE stock's Price/Earning ratio is 28.65.
Our analysis grades 4519:TSE stock's Price / Earning ratio at F. This means that 4519:TSE stock's Price/Earning ratio is above 50% of the stocks in the Drug Manufacturers - General sector in the TSE exchange.
Based on this 4519:TSE may be fairly valued for its sector
The last closing price of 4519:TSE's stock was JPY 6,974.00.
The most recent market capitalization for 4519:TSE is JPY 11,072.64B.
Unfortunately we do not have enough analyst data on 4519:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Chugai Pharmaceutical Co. Ltd.'s stock.
As per our most recent records Chugai Pharmaceutical Co. Ltd. has 7,604 Employees.
Chugai Pharmaceutical Co. Ltd.'s registered address is 2-1-1 Nihonbashi-Muromachi, Chuo, Japan, 103-8324.
You can get more information about it from Chugai Pharmaceutical Co. Ltd.'s website at https://www.chugai-pharm.co.jp.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4519:TSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
